[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Wren Laboratories LLC\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100627897",false,"NCT07454603","A Prospective Clinical Trial Evaluating PROSTest, a Blood-Based Molecular Assay, for Risk Stratification and Biopsy Decision Support in Men With Suspected Prostate Cancer","PROSTest_STRAT","Inclusion Criteria:\n\n* elevated PSA and\u002For abnormal digital rectal examination\n\nExclusion Criteria:\n\n* Previous Prostate cancer diagnosis","MALE","45 Years","80 Years",{"count":19,"type":20},1500,"ESTIMATED","OBSERVATIONAL","This prospective observational study will enroll men referred for prostate biopsy due to elevated PSA and\u002For abnormal digital rectal examination, with or without pre-biopsy MRI. Peripheral blood will be collected prior to biopsy for PROSTest analysis. Biopsy histopathology will serve as the reference standard. PROSTest results will be analyzed blinded to pathology.",[24,25,26],"Prostate Cancer","Urology","Prostate Cancer (Diagnosis)",[28,29,30],"BIOPSY","MRI","PROSTATE CANCER","NOT_YET_RECRUITING","2026-03-02",{"date":34,"type":35},"2026-03-06","ACTUAL",{"date":37,"type":20},"2026-03-15",{"date":39,"type":20},"2027-06-01",{"name":41,"class":42},"Wren Laboratories LLC","INDUSTRY",""]